- In January 2025, Organovo, a leader in bioprinting technologies, announced the successful development of a bioprinted liver model capable of replicating human liver functionality in vitro. This model can revolutionize drug discovery and improve preclinical testing and personalized treatment options for liver diseases. The model mimics the complex architecture of human tissue, paving the way for advancements in organ transplantation
- In February 2024, BICO Group AB (Cellink) launched DNA Studio 4 Vault, a bioprinting software, providing users with confidence and trust in their documentation, enabling a faster translation from the research lab to the clinic
- In February 2024, Merck KGaA (Germany) established a distribution center in Brazil with an investment of USD 21.7 million to better serve its Life Science customers for faster deliveries in the region
- In April 2023, Aspect Biosystem Ltd (Canada) and Novo Nordisk (Denmark) entered a collaboration, development, and Licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body to deliver a new class of truly disease-modifying treatments for diabetes and obesity
- In April 2023, CollPlant Biotechnologies Ltd (Israel) and Stratasys (US) entered a collaboration for the development of collaborated to develop a solution to bio-fabricate human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks
